Adaptimmune Therapeutics plc. (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting ceremony this morning at 10:30am at the Navy Yard in Philadelphia to celebrate the opening of its newly constructed U.S. headquarters and base for clinical and manufacturing operations. Developed by Liberty Property Trust (NYSE: LPT) and Synterra Partners, and under advisement of CBRE’s Life Science Advisory and Project Management Group, Adaptimmune’s 47,400 square foot facility, located at 351 Rouse Boulevard will include a state-of-the-art cGMP manufacturing facility designed to support the Company’s clinical development objectives and the initial commercialization of novel engineered immunotherapies for cancer. Adaptimmune’s Navy Yard facility currently houses 91 employees; this number is expected to grow to 120 by the end of 2017.
https://www.navyyard.org/theyardblog/wp-content/uploads/2017/03/Ribbon-cutting.jpg 3024 4032 The Navy Yard https://www.navyyard.org/theyardblog/wp-content/uploads/2019/02/Navy-Yard-Logo.jpg The Navy Yard2017-03-01 12:17:242017-05-26 13:10:45Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia